A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Aug 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 2, 2008
CompletedFirst Posted
Study publicly available on registry
December 3, 2008
CompletedStudy Start
First participant enrolled
August 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2011
CompletedJuly 25, 2011
July 1, 2011
1.9 years
December 2, 2008
July 21, 2011
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients having completed study A4001029 in Canada and still deriving clinical benefit.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ViiV Healthcarelead
- Pfizercollaborator
Study Sites (1)
Pfizer Investigational Site
Montreal, Quebec, H3G 1A4, Canada
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
December 2, 2008
First Posted
December 3, 2008
Study Start
August 1, 2009
Primary Completion
July 1, 2011
Study Completion
July 1, 2011
Last Updated
July 25, 2011
Record last verified: 2011-07